Page 89 - Read Online

Page 22 of 22 Guerriero et al. Hepatoma Res 2019;5:6 I http://dx.doi.org/10.20517/2394-5079.2018.108

hepatitis B virus infection. Int J Clin Exp Med 2015;8:18462-8.
144. Zheng F, Liao YJ, Cai MY, Liu TH, Chen SP, et al. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in
vivo by repressing multiple targets. PLoS Genet 2015;11:e1004873.
145. Xu Y, Bu X, Dai C, Shang C. High serum microRNA-122 level is independently associated with higher overall survival rate in
hepatocellular carcinoma patients. Tumour Biol 2015;36:4773-6.
146. Zhuang LP, Meng ZQ. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int
2015;2015:731781.
147. Cho HJ, Kim JK, Nam JS, Wang HJ, Lee JH, et al. High circulating microRNA-122 expression is a poor prognostic marker in patients
with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. Clin Biochem 2015;48:1073-8.
148. Kim SS, Cho HJ, Nam JS, Kim HJ, Kang DR, et al. Plasma MicroRNA-21, 26a, and 29a-3p as predictive markers for treatment
response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Korean Med Sci 2018;33:e6.
149. Cho HJ, Kim SS, Nam JS, Kim JK, Lee JH, et al. Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients
with hepatocellular carcinoma who underwent curative treatment. Clin Res Hepatol Gastroenterol 2017;41:181-9.
150. Xiang ZL, Zhao XM, Zhang L, Yang P, Fan J, et al. MicroRNA-34a expression levels in serum and intratumoral tissue can predict
bone metastasis in patients with hepatocellular carcinoma. Oncotarget 2016;7:87246-56.
151. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, et al. Identification of a bona fide microRNA biomarker in serum exosomes
that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 2015;112:532-8.
152. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, et al. MicroRNA-423-5p promotes autophagy in cancer cells and is
increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids 2015;4:e233.
153. El-Tawdi AH, Matboli M, Shehata HH, Tash F, El-Khazragy N, et al. Evaluation of circulatory RNA-based biomarker panel in
hepatocellular carcinoma. Mol Diagn Ther 2016;20:265-77.
154. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int
2013;2013:136106.
155. El-Tawdi AH, Matboli M, El-Nakeep S, Azazy AE, Abdel-Rahman O. Association of long noncoding RNA and c-JUN expression in
hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:869-77.
156. Tang J, Zhuo H, Zhang X, Jiang R, Ji J, et al. A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and
metastasis in hepatocellular carcinoma. Cell Death Dis 2014;5:e1549.
157. Wang X, Zhang W, Tang J, Huang R, Li J, et al. LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an
epidermal growth factor receptor-dependent pathway. Cell Death Dis 2016;7:e2130.
158. Tang J, Jiang R, Deng L, Zhang X, Wang K, et al. Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis
and metastasis in hepatocellular carcinoma. Oncotarget 2015;6:4505-15.
159. Konishi H, Ichikawa D, Yamamoto Y, Arita T, Shoda K, et al. Plasma level of metastasis-associated lung adenocarcinoma transcript 1
is associated with liver damage and predicts development of hepatocellular carcinoma. Cancer Sci 2016;107:149-54.
160. Jing W, Gao S, Zhu M, Luo P, Jing X, et al. Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma. Oncol Rep
2016;36:1085-92.
161. Wang K, Guo WX, Li N, Gao CF, Shi J, et al. Serum LncRNAs profiles serve as novel potential biomarkers for the diagnosis of HBV-
positive hepatocellular carcinoma. PLoS One 2015;10:e0144934.